NCT07493122
Study of IMC-S118AI in Type 1 Diabetes
Not Yet Recruiting · Phase 1 · Immunocore Ltd · registry updated 2026-03-25
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Inclusion
- Body mass index (BMI): 18 to 25 kg/m2
- History of a diagnosis of T1D
- HLA type: HLA-A\*02:01
- Shows signs of remaining beta-cell function
Exclusion
- Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes)
- History of recurrent hypoglycaemia due to non-compliance with insulin regimens
- Prior treatment with immunomodulating therapy for T1D
- Have a history of cardiovascular disease or impaired cardiac function
- Current diagnosis of a malignancy or any history of malignancy